BETAGAN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETAGAN is an ophthalmic solution (eye drops) approved in 1985 for treating glaucoma and ocular hypertension. It is a small-molecule beta-blocker that reduces intraocular pressure by decreasing aqueous humor production. The drug represents a mature, legacy ophthalmology therapeutic.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team likely shifting to lifecycle management and cost optimization strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BETAGAN offers limited career growth opportunities given its LOE-approaching status and zero linked job openings; roles are primarily defensive and focused on protecting market share and managing transition. Professionals joining this portfolio should expect focus on cost management, generic competition strategies, and maintaining relationships with established customers rather than market expansion.
Product Manager (Lifecycle)
Worked on BETAGAN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.